UPAR antibodies and fusion proteins with the same
US12338293B2 · kind B2 · utility
0Cited by
25References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 23, 2022 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Jun 7, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides urokinase plasminogen activator receptor (uPAR) binding polypeptides (e.g., uPAR antigen binding proteins), and fusion proteins comprising said uPAR binding polypeptides and a cytokine or variant thereof. The disclosure further provides pharmaceutical compositions comprising the uPAR binding polypeptides and fusion proteins of the disclosure and methods of treating cancer with the same. The disclosure further provides engineered IL-12 p35 and p40 polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.